CompletedNCT02214134
SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Principal Investigator
- Benjamin Besse, MD, PhDGustave Roussy, Cancer Campus, Grand Paris
- Intervention
- Tumour markers testing(genetic)
- Enrollment
- 539 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2021
Study locations (17)
- Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels, Belgium
- Universitair Ziekenhuis Antwerpen, Edegem, Belgium
- U.Z. Leuven - Campus Gasthuisberg, Leuven, Belgium
- CHU de Lyon - Hopital Louis Pradel, Lyon, France
- Assistance Publique - Hopitaux de Marseille - Hopital Nord, Marseille, France
- CHU Toulouse - Hopital Larrey, Toulouse, France
- Gustave Roussy Cancer Campus, Villejuif, France
- St. James's Hospital, Dublin, Ireland
- Ospedale S. Luigi Gonzaga - Universita Di Torino, Torino, Italy
- Medical University Of Gdansk, Gdansk, Poland
- University Clinic Golnik, Golnik, Slovenia
- Hospital General Vall D'Hebron, Barcelona, Spain
- Hospital Universitario 12 De Octubre, Madrid, Spain
- Centre Hospitalier Universitaire Vaudois - Lausanne, Lausanne, Switzerland
- Royal Marsden Hospital - Kingston Hospital, Kingston upon Thames, United Kingdom
- +2 more locations on ClinicalTrials.gov
Collaborators
ETOP IBCSG Partners Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02214134 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital
- RECRUITINGPHASE1NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsInSilico Medicine Hong Kong Limited